Charles River Laboratories International, Inc. (CRL) Stock

Charles River Laboratories International, Inc. (CRL) is a Technology stock trading at $185.09 (as of 2026-06-18), with a market capitalization of $8.70B and a trailing P/E of -50.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Charles River Laboratories International provides non-clinical contract research services and related products for drug discovery, non-clinical development, and safety testing. It operates through three segments—Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions—serving clients in the United States, Europe, Canada, Asia Pacific, and internationally.

Valuation — source: SEC EDGAR (first-party)
Price	$185.09
Market Cap	$8.70B
P/E Ratio	-50.5
EV / EBITDA	21.0
Price / Book	3.07
Price / Sales	2.24
DCF Value (model)	$150.67
DCF Upside vs Price	-18.6%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.02B
Net Margin	-3.6%
Return on Equity	-6.3%
Debt / Equity	0.00
Current Ratio	1.36
Revenue Growth (YoY)	1.2%
EPS Growth (YoY)	-160.0%
FCF Growth (YoY)	-113.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.28 (grey)

Valuation vs Sector & Industry
Stock P/E	-50.5
Sector P/E (Technology)	32.6
Industry P/E (Business Services)	27.1
vs Sector	-254.8%
vs Industry	-286.6%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($1.17B)
Institutional Holders Tracked	10
Congressional Trades (recent)	9

Company
Sector	Technology
Industry	Business Services
CEO	James C. Foster
Employees	18,700
Country	US
IPO Date	2000-06-23

Related Companies (Business model: Clinical Labs / CRO Services; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.